HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates a Buy rating on Vor Biopharma (NASDAQ:VOR) and maintains a $17.5 price target.

June 12, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reiterates Buy rating on Vor Biopharma and maintains a $17.5 price target.
The Buy rating reiteration by HC Wainwright & Co. analyst Swayampakula Ramakanth on Vor Biopharma (NASDAQ:VOR) and maintaining the $17.5 price target indicates a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential and may attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100